Collegium Pharmaceutical Inc (COLL) valuation
Collegium Pharmaceutical P/E ratio history
Collegium Pharmaceutical trades at 19.2 times its earnings over the last twelve months and 3.2 times the earnings analysts expect over the next twelve. At its last 5 fiscal year ends its P/E ranged from 11.1 (year to Dec 2021) to 27.1 (year to Dec 2025), with a median of 26.1.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $46.30 | $1.71 | 27.1 | 6.1 |
| Dec 31, 2024 | $28.65 | $1.86 | 15.4 | 4.4 |
| Dec 31, 2023 | $30.78 | $1.18 | 26.1 | 8.5 |
| Dec 31, 2022 | $23.20 | -$0.74 | n/m | — |
| Dec 31, 2021 | $18.68 | $1.69 | 11.1 | 4.4 |
| Dec 31, 2020 | $20.03 | $0.76 | 26.4 | — |
| Dec 31, 2019 | $20.58 | -$0.68 | n/m | — |
| Dec 31, 2018 | $17.17 | -$1.20 | n/m | — |
| Dec 31, 2017 | $18.46 | — | n/m | — |
| Dec 31, 2016 | $15.57 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Collegium Pharmaceutical valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Collegium PharmaceuticalCOLL | $772M | 19.2 | 3.2 | 1.0 |
| PhreesiaPHR | $769M | 69.1 | 8.7 | 1.5 |
| Varex ImagingVREX | $776M | 35.4 | 18.2 | 0.9 |
| AdapthealthAHCO | $790M | — | — | 0.2 |
| Beta BionicsBBNX | $754M | — | — | 5.9 |
| Cytek BiosciencesCTKB | $792M | — | — | 3.8 |
| ArdelyxARDX | $748M | — | — | 1.7 |
| OmniabOABI | $741M | — | — | 19.3 |
| OrthopediatricsKIDS | $806M | — | — | 3.1 |
| Peer median | 52.3 | 13.4 | 2.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: COLL financials · COLL returns
No forecast, no recommendation. This page describes Collegium Pharmaceutical Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.